Sector & Market
Viridian Shares Fall 25% After Amgen Data
Viridian Therapeutics stock plunged 25.2% on Monday following Amgen's positive Phase 3 TEPEZZA OBI trial results.
Amgen's TEPEZZA OBI achieved a 77% proptosis response versus 19.6% placebo, outperform
